Skip to content

Study on Diagnostic Biomarkers and Screening Models for Genitourinary Cancer Based on Plasma Metabolomics

Study on Diagnostic Biomarkers and Screening Models for Genitourinary Cancer Based on Plasma Metabolomics

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400084816
Enrollment
Unknown
Registered
2024-05-24
Start date
2019-12-10
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Genitourinary Cancer

Interventions

Gold Standard:The postoperative pathological diagnosis is malignant tumor of the urinary system.
Index test:Plasma metabolites content
Plasma metabolites-based diagnostic model

Sponsors

Peking University First Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. The inclusion criteria for participants with genitourinary cancer are: (1) diagnosis of genitourinary cancer through imaging modalities such as ultrasound, CT, or MRI, with a planned surgical intervention; (2) signing informed consent and agreeing to participate in this study. 2. The inclusion criteria for the healthy control group are: (1) age = 18 years; (2) individuals planning to undergo a general health examination; and (3) signing informed consent and agreeing to participate in this study.

Exclusion criteria

Exclusion criteria: 1. History of malignancy. 2. Preoperative history of receiving anti-tumor treatments such as radiotherapy, chemotherapy, targeted therapy, etc.

Design outcomes

Primary

MeasureTime frame
Plasma metabolites content;Area under the curve;Sensitivity;Specificity;

Secondary

MeasureTime frame
Accuracy;

Countries

China

Contacts

Public ContactZhou Liqun

Department of Urology, Peking University First Hospital

zhoulqmail@163.com+86 136 0123 9241

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026